Main points of complete mesoeolic excision for right-hemi colorectal cancer and comparation with traditional surgery in the efficacy
10.3760/cma.j.issn.1673-4203.2014.02.009
- VernacularTitle:右半结肠癌全结肠系膜切除术要点及与传统手术疗效对比
- Author:
Yang HE
;
Xiaohuang TU
;
Jingxiang SONG
;
Zaizhong ZHANG
- Publication Type:Journal Article
- Keywords:
Right-hemi colorectal cancer;
Complete mesoeolic excision;
Surgical procedures,operative;
Treatment outcome;
Postoperative complications
- From:
International Journal of Surgery
2014;41(2):97-101,封3
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical safety and efficacy of complete mesoeolic excision (CME) for right-hemi colorectal cancer with traditional surgical treatment.Methods Collectting the clinical data of 69 cases,who randonly divided into two groups,A group induced 38 cases and were implemented regular CME,and B group induded 31 cases which were implemented traditional surgery of right-hemi colorectal cancer patients from the Department of General surgery,Fuzhou General Hospital of Nanjing Military Region from Jan.1 2010 to Oct.1 2010,and comparing the safety and efficacy.Results The differences between and traditional surgery in terms of operation time,blood loss,exhaust and defecation time,hospitalization time,the rate of postoperative complication,the number of removed lymph node of Ⅰ and Ⅱ phase,3-year recurrence rate of Ⅱ phase,3-year survival rate of Ⅱ phase and the number of removed lymph node of Ⅲ phase in mesentery root were not significant.The differences in terms of the number of removed lymph node of Ⅲ phase(22.76 ± 6.94,15.11 ± 7.85),3-year recurrence rate of Ⅲ phase(5.88％,45.45％),3-year survival rate of Ⅲ phase (94.12％,63.64％),the total number of removed lymph node(20.56 ± 7.11,13.92 ± 6.62),3-year overall recurrence rate(7.89％,29.03％)and 3-year overall survival rate (94.74％,77.42％) were significant.Conclusions Comparing with traditional surgery,CME significantly benefits the patients of right-hemi colorectal cancer with stage Ⅲ,but not for patients with stage Ⅰ and Ⅱ.
